• CDC
  • Heart Failure
  • Cardiovascular Clinical Consult
  • Adult Immunization
  • Hepatic Disease
  • Rare Disorders
  • Pediatric Immunization
  • Implementing The Topcon Ocular Telehealth Platform
  • Weight Management
  • Screening
  • Monkeypox
  • Guidelines
  • Men's Health
  • Psychiatry
  • Allergy
  • Nutrition
  • Women's Health
  • Cardiology
  • Substance Use
  • Pediatrics
  • Kidney Disease
  • Genetics
  • Complimentary & Alternative Medicine
  • Dermatology
  • Endocrinology
  • Oral Medicine
  • Otorhinolaryngologic Diseases
  • Pain
  • Gastrointestinal Disorders
  • Geriatrics
  • Infection
  • Musculoskeletal Disorders
  • Obesity
  • Rheumatology
  • Technology
  • Cancer
  • Nephrology
  • Anemia
  • Neurology
  • Pulmonology

ADA 2018: New Basal Insulins go Head-to-Head

Slideshow

How do 2nd generation basal insulin formulations perform vs their predecessors? We report highlights of 3 important studies from the ADA 78th Scientific Sessions.

Recent Videos
New Research Amplifies Impact of Social Determinants of Health on Cardiometabolic Measures Over Time
Related Content
More than Half of US Adults Eligible for Semaglutide: Daily Dose / image credit: ©New Africa/AdobeStock

More than Half of US Adults Eligible for Semaglutide: Daily Dose

Sydney Jennings
December 9th 2024
Article

Your daily dose of the clinical news you may have missed.

Site Logo

Man With Newly Diagnosed Type 2 Diabetes: What HbA1c Goal-And How to Get There?

Edward J. Shahady, MD
May 8th 2013
Podcast

The patient, an active 49-year-old man, had an HbA1c of 8.6 after diabetes was first diagnosed. It’s now 7.6 with metformin and lifestyle measures. Is the current A1c goal adequate, or should you treat more aggressively?

More than Half of US Adults May Be Eligible for Semaglutide Therapy / image credit Dhruv Kazi, MD, MSc, MS Smith Center for Outcomes Research in Cardiology

More than Half of US Adults May Be Eligible for Semaglutide Therapy, Accordng to New Estimates

Grace Halsey
November 21st 2024
Article

Millions of US adults could benefit from semaglutide treatment for diabetes, obesity, and/or CV disease but insurance isn't guaranteed and the drug is costly.

Challenging Case: A Patient With Hypoglycemia and High HbA1c

Challenging Case: A Patient With Hypoglycemia and High HbA1c

Edward J. Shahady, MD
March 4th 2013
Podcast

Hypoglycemia in type 2 diabetes patients can be the result of insulin or sulfonylureas.

Data Published on Sotagliflozin Used to Reduce HbA1c in Adults with Type 1 Diabetes and Kidney Disease / image credit David Cherney UHN Research

Data Published on Sotagliflozin Used to Reduce HbA1c in Adults with Type 1 Diabetes and Kidney Disease

Grace Halsey
November 7th 2024
Article

The data, published in JASN, were presented last week to an FDA advisory committee considering recommending sotagliflozin as an adjunct to insulin in adults with T1D and CKD.

Sotagliflozin Setback: Cautionary FDA AdComm Vote Reflects Continued Concern for Negative Risk/Benefit Ratio in T1D with CKD / image credit ©Tada Images/stock.adobe.com

Sotagliflozin Setback: Cautionary FDA AdComm Vote Reflects Continued Concern for Negative Risk/Benefit Ratio in T1D with CKD

Grace Halsey
November 1st 2024
Article

The FDA's Endocrinologic and Metabolic Drugs Advisory Committee voted 11 to 3 against recommending the SGLT1/SLGT2 inhibitor to treat adults with T1D and CKD.

© 2024 MJH Life Sciences

All rights reserved.